Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL956172 | 1.00 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1KDM4EPOLBMEN1 | |
| SCHEMBL957552 | 0.94 | POLB (0.44) | SIGMAR1ALDH1A1POLBMEN1HTT | |
| SCHEMBL957553 | 0.94 | POLB (0.44) | SIGMAR1ALDH1A1POLBMEN1HTT | |
| SCHEMBL957550 | 0.94 | POLB (0.44) | SIGMAR1ALDH1A1POLBMEN1HTT | |
| SCHEMBL8272456 | 0.86 | SIGMAR1 (0.41) | SIGMAR1ALDH1A1POLBMEN1HTT | |
| SCHEMBL958311 | 0.86 | SIGMAR1 (0.41) | SIGMAR1ALDH1A1POLBMEN1HTT | |
| Oxalic Acid SCHEMBL954304 | 0.86 | CA1 (0.41) | SIGMAR1ALDH1A1KDM4EPOLBKMT2A | |
| Oxalic Acid SCHEMBL955037 | 0.86 | CA1 (0.41) | SIGMAR1ALDH1A1KDM4EPOLBKMT2A | |
| Oxalic Acid SCHEMBL954305 | 0.86 | CA1 (0.41) | SIGMAR1ALDH1A1KDM4EPOLBKMT2A | |
| Oxalic Acid SCHEMBL955035 | 0.86 | CA1 (0.41) | SIGMAR1ALDH1A1KDM4EPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394797-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-12 | — | — | US | claimed |
| EP-1781619-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2011-08-17 | — | — | EP | claimed |
| US-7829559-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-11-09 | — | — | US | claimed |
| US-20070232585-A1 | Sigma Receptor Inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-04 | — | — | US | claimed |
| EP-1781619-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | claimed |
| WO-2006021463-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | claimed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| US-8394797-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| EP-1781619-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2011-08-17 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| EP-2292237-A1 | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-03-09 | — | — | EP | disclosed |
| US-20110015183-A1 | SUBSTITUTED PYRAZOLE SIGMA RECEPTOR ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-01-20 | — | — | US | disclosed |
| US-7829559-B2 | Substituted pyrazole sigma receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-11-09 | — | — | US | disclosed |
| US-20070232585-A1 | Sigma Receptor Inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-04 | — | — | US | disclosed |
| EP-1781619-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021463-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015183-A1 | SUBSTITUTED PYRAZOLE SIGMA RECEPTOR ANTAGONISTS | SIGMAR1, OPRK1, OPRD1 | SIGMAR1 1/4885ALDH1A1 1244/4885KDM4E 4679/4885 |
| US-20070232585-A1 | Sigma Receptor Inhibitors | SIGMAR1, OPRK1, OPRL1 | SIGMAR1 1/4885ALDH1A1 1180/4885KDM4E 4677/4885 |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | SIGMAR1 3/4885ALDH1A1 1524/4885KDM4E 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.